TenQ · fact sheet · filings current to · price as of
Bristol Myers Squibb (BMY)
A mixed picture - strengths and real weaknesses - 24 of 36 checks passed.
Latest close : $66.82, -1.9% on the day; -1.9% from the 52-week high. Refreshed every trading night.
Full analysis: report · all charts. Financial statements are computed from SEC EDGAR XBRL filings, current to . The share price and everything built on it (market cap, multiples, yields, the Value and Trend checks) are refreshed every trading night; this page shows the close of . Not investment advice.
Key figures
| Share price (delayed close) | $66.82 |
| Market cap | $136.5B |
| 52-week range | $41.21 - $68.09 |
| P/E | 14.7x |
| P/E, own 9-year median | 16.7x |
| P/S | 2.8x |
| Free cash flow yield | 8.4% |
| Dividend yield | 3.7% |
| Revenue (TTM) | $49.2B |
| Net income (TTM) | $9.3B |
| Free cash flow (TTM) | $11.4B |
| Gross margin | 62.5% |
| Operating margin | - |
| Return on equity | 41.6% |
| Revenue growth (1y) | +3.1% |
| Revenue CAGR (3y) | +1.4% |
| Debt / equity | 1.93x |
| Cash & short-term investments | $8.9B |
| Shares outstanding | 2,042.7m (cover page of the latest filing, 2026-07-22) |
The score: 24 of 36 checks passed
Six chapters, six pass/fail checks each. Five are computed from the filings; Trend is price behaviour, and says so.
Is BMY stock cheap or expensive right now?
Value · 2 of 6 checks passed. Expensive against its own history and its sector - you're paying up for what you get. chapter →
Is Bristol Myers Squibb still growing?
Growth · 3 of 6 checks passed. Growing, but with caveats - revenue +3.1% over the last year. chapter →
Does Bristol Myers Squibb make real money?
Quality · 6 of 6 checks passed. Rare profitability: margins and returns on capital are well above its peers. chapter →
Can Bristol Myers Squibb survive a bad year?
Health · 3 of 6 checks passed. Financially sound overall, with one or two things worth watching. chapter →
What does Bristol Myers Squibb hand back to shareholders?
Shareholder returns · 4 of 6 checks passed. Cash comes back to owners, with a caveat or two in the checks below. chapter →
Which way is BMY trending?
Trend analysis · 6 of 6 checks passed. The market agrees: the stock is in a healthy uptrend on every horizon. chapter →
Are insiders buying or selling BMY?
Open-market buys: $0.00 · sells: $2M, across the recent Form 4 filings. detail →
Other pharma and chemicals we cover: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · Procter & Gamble (PG) · Amgen (AMGN) · every company →
Method: figures computed deterministically from SEC EDGAR XBRL (companyfacts, frames, financial-statement-and-notes datasets, Form 4); prices delayed end-of-day. Scores count transparent pass/fail checks. Missing data is shown as missing, never estimated. Last changed . © TenQ - cite with a link to this page.